ATHE - Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting | Benzinga
– Positive Efficacy Data for ATH434 in a Primate Model of Parkinson's Disease to be Presented at International Conference –
– Baseline Biomarker Data to be Presented from Ongoing ATH434-201 Phase 2 Clinical Trial –
MELBOURNE, Australia and SAN FRANCISCO, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics ((ASX: ATH, NASDAQ:ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that three posters from the Company's development pipeline will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting taking place April 13-18, 2024, in Denver, Colorado, USA.
"We are thrilled to be presenting at this prestigious international neurology conference, including new baseline biomarker data on ATH434 from our ongoing Phase 2 randomized, double blind clinical trial in multiple system atrophy (MSA), as well as compelling preclinical primate data on ATH434 in Parkinson's disease," said, David Stamler, M.D., Chief Executive Officer of Alterity. "In addition, we remain in the vanguard of biomarker evaluation of MSA, as our partners at Vanderbilt University will present important data from our bioMUSE natural history study. AAN promises to be a very productive conference for us as we advance our MSA program toward data later this year and expand our development toward Parkinson's disease."
| Title: |
| A Phase 2 Study of ATH434, a Novel Inhibitor of ?-Synuclein Aggregation, for the Treatment of Multiple System Atrophy (MSA) |
| Lead Author: |
| David Stamler, M.D., Chief Executive Officer of Alterity Therapeutics |
| Date/Time: |
| Sunday, April 14, from 11:45 a.m. 12:45 p.m. Mountain Time (U.S.) |
| Title: |
| Neurofilament Light Chain and Clinical Progression in Early Multiple System Atrophy |
| Lead Author: |
| Daniel O. Claassen, M.D., M.S., Professor of Neurology, Vanderbilt University Medical Center |
| Date/Time: |
| Monday, April 15, from 5:30 p.m. to 6:30 p.m. Mountain Time (U.S.) |
| Title: |
| Effects of ATH434, a Clinical-phase Small Molecule with Moderate Affinity for Iron, in a Parkinson's Disease Model in Macaques |
| Lead Author: |
| Margaret Bradbury, Vice President, Research and Nonclinical Development, Alterity Therapeutics |
| Date/Time: |
| Tuesday, April 16, from 11:45 a.m. to 12:45 p.m. Mountain Time (U.S.) |
About ATH434
Alterity's lead candidate, ATH434, is an oral agent designed to inhibit the aggregation of pathological proteins implicated in neurodegeneration. ATH434 has been shown preclinically to reduce ?-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential ...